防腐劑治療精神分裂？

新聞 02-06

乾貨 | 靠譜 | 實用

第 28 彈

Title：Common Preservative in Food May Help Schizophrenia Therapy

Toss around the word preservative these days, and you』re sure to get a look of detestation from a fair number of people. The much-maligned molecules have come under intense scrutiny in recent years as contributing factors to a host of medical issues—often with scant scientific evidence to support even casual links. Yet now, researchers at the China Medical University in Taiwan may have just stumbled upon a new use for the common food preservative sodium benzoate in treating schizophrenia. Findings from the new study—published recently in Biological Psychiatry tin an article entitled 「Sodium Benzoate, a D-amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial」—show that the preservative improves symptoms in clozapine-resistant schizophrenia patients.

"Clozapine is considered the last-line antipsychotic agent for patients with refractory schizophrenia," explained senior study investigator Hsien-Yuan Lane, M.D., Ph.D., a research scientist at China Medical University, in reference to patients whose symptoms do not respond to available antipsychotics.

An estimated 40% to 70% of patients with refractory schizophrenia fail to improve, even with clozapine, and referred to as "clozapine-resistant," exhausting all potential options for treatment. This new study is the first to demonstrate that sodium benzoate—which has been shown to enhance other antipsychotic drugs—works in clozapine-resistant patients.

"If the finding can be confirmed, this approach may bring hope for treating patients with the most refractory schizophrenia," Dr. Lane remarked.

In this randomized, double-blind, placebo-controlled trial, the researchers examined 60 patients with schizophrenia that were all taking clozapine. Participants received either a placebo or sodium benzoate as an add-on treatment for six weeks. The investigators tested two different doses of sodium benzoate (1 or 2 grams per day) to find which offered the biggest impact on symptoms with minimal side effects.

「Both doses of sodium benzoate produced better improvement than placebo in the Scales for the Assessment of Negative Symptoms (SANS),」 the authors reported, and 「2-g/day sodium benzoate also produced better improvement than placebo in PANSS [Positive and Negative Syndrome Scale]-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated with the improvement of PANSS total and PANSS-positive score in the sodium benzoate group.」

Compared with the placebo, sodium benzoate improved negative symptoms, such as lack of emotion and motivation, which have a greater influence on a patient"s functional outcome than the more prominent psychotic symptoms. The higher dose of sodium benzoate also improved ratings of overall symptoms and quality of life. Although sodium benzoate has improved cognitive function when combined with other antipsychotics in previous studies, the add-on treatment had no influence on cognitive function in this study. The authors hypothesized that a higher dose or longer duration of treatment might be needed to observe cognitive effects. Importantly, the patients taking sodium benzoate had no side effects, confirming the treatment is safe to use at the doses tested.

Sodium benzoate works by preventing the breakdown of D-serine, a brain chemical that plays an important role in signaling that is disrupted in the brains of people with schizophrenia.

"Receptors for D-serine are long-standing targets for medication development in schizophrenia and sodium benzoate is probably the first meaningful tool that we have had to influence this target," noted editor-in-chief of Biological Psychiatry John Krystal, M.D., a professor at Yale University Medical School.

Although more studies are needed to learn how sodium benzoate enhances clozapine treatment in these patients, Dr. Krystal concluded that "this study highlights the importance for schizophrenia treatment of understanding the molecular switches that can be thrown to normalize brain circuit function."

投稿規則

1.本次活動為自願參加，關注每日文章推送即可，每周一、周三、周五發布翻譯稿件，周二、周四、周六進行翻譯文章刊登；每篇文章投稿時間為2天，周一的推送截止翻譯日期為當周周三，以此類推，節假日順延投稿時間

2.投稿形式：以word文字版為準，文件名為：第幾彈+姓名。以附件形式發送至投稿郵箱。

3.參與活動均可獲得轉化醫學網小禮品（價值30元左右）1份，被錄取的文章將得到100元/篇的稿酬；您可在郵件正文或附件中留下地址號碼領取禮物，因為禮物的郵寄可能需要一段時間，請您耐心等待

4.投稿文件轉化醫學網編輯部收到後，會進行審核，我們會在2~3個工作日內給與回復

5.得到文稿被錄用郵件回復的作者可添加轉化醫學網內容部同事微信領取相應微信紅包

6.本次活動最終解釋權歸轉化醫學網所有

END

活動